Clinical Trial Update: AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure [Phase 2]

View source ↗

Summary

A Phase 2 trial update for AR-12286 fixed-dose combination to reduce elevated intraocular pressure in glaucoma and ocular hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• AR-12286 fixed-dose combination

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED